journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://read.qxmd.com/read/30772418/paediatric-pulmonary-embolism-a-pathway-to-improved-outcomes
#1
Vera Ignjatovic
No abstract text is available yet for this article.
February 13, 2019: Lancet Haematology
https://read.qxmd.com/read/30772417/outcomes-and-risk-factors-of-massive-and-submassive-pulmonary-embolism-in-children-a-retrospective-cohort-study
#2
Marie-Claude Pelland-Marcotte, Catherine Tucker, Alicia Klaassen, Maria Laura Avila, Ali Amid, Nour Amiri, Suzan Williams, Jacqueline Halton, Leonardo R Brandão
BACKGROUND: Little is known about severe pulmonary embolism in children. We aimed to report pulmonary embolism outcomes, identify risk factors for unfavourable outcomes, and evaluate the discriminative ability of two clinical-severity indices in children. METHODS: In this retrospective cohort study, we included consecutive patients aged 18 years or younger with acute pulmonary embolism, objectively diagnosed radiologically or pathologically, between Jan 1, 2000, and Dec 31, 2016, from two Canadian paediatric hospitals (The Hospital for Sick Children, Toronto, ON, and the Children's Hospital of Eastern Ontario, Ottawa, ON)...
February 13, 2019: Lancet Haematology
https://read.qxmd.com/read/30738834/a-clinical-prediction-model-for-outcome-and-therapy-delivery-in-transplant-ineligible-patients-with-myeloma-uk-myeloma-research-alliance-risk-profile-a-development-and-validation-study
#3
Gordon Cook, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Vallari Shah, Martin F Kaiser, Sarah R Brown, Walter M Gregory, J Anthony Child, Faith E Davies, Gareth J Morgan, David A Cairns, Graham H Jackson
BACKGROUND: Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict overall survival in patients with multiple myeloma who were ineligible for stem-cell transplantation. METHODS: We used patient data from two randomised controlled trials done in patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation (the NCRI Myeloma XI study [NCRI-XI, n=1852] and the MRC Myeloma IX study [MRC-IX, n=520]), to develop the UK Myeloma Research Alliance Risk Profile (MRP) for overall survival...
February 6, 2019: Lancet Haematology
https://read.qxmd.com/read/30738833/frailty-in-multiple-myeloma-the-need-for-harmony-to-prevent-doing-harm
#4
Sonja Zweegman, Alessandra Larocca
No abstract text is available yet for this article.
February 6, 2019: Lancet Haematology
https://read.qxmd.com/read/30704924/eltrombopag-use-in-higher-risk-myeloid-cancers-fitting-a-square-pag-into-a-round-hole
#5
Rena Buckstein
No abstract text is available yet for this article.
January 28, 2019: Lancet Haematology
https://read.qxmd.com/read/30704923/eltrombopag-treatment-during-induction-chemotherapy-for-acute-myeloid-leukaemia-a-randomised-double-blind-phase-2-study
#6
Noelle Frey, Jun Ho Jang, Jeff Szer, Árpád Illés, Hee-Je Kim, Ron Ram, Beng H Chong, Jacob M Rowe, Elena Borisenkova, Jane Liesveld, Eric S Winer, Azzeddine Cherfi, Vassilios Aslanis, Farhat Ghaznawi, Stephen Strickland
BACKGROUND: Patients with acute myeloid leukaemia frequently have thrombocytopenia during induction chemotherapy. Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet production by a similar mechanism to endogenous thrombopoietin. This study investigated safety and efficacy of eltrombopag versus placebo during anthracycline-based induction treatment of patients with acute myeloid leukaemia. METHODS: In this randomised, double-blind, phase 2 study, treatment-naive patients were recruited from clinical centres across 10 countries (Australia, Belgium, Canada, Greece, Hungary, Israel, South Korea, Poland, Russia, and the USA)...
January 28, 2019: Lancet Haematology
https://read.qxmd.com/read/30642819/safety-and-activity-of-ibrutinib-in-combination-with-nivolumab-in-patients-with-relapsed-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukaemia-a-phase-1-2a-study
#7
Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch, Maria Dolores Caballero Barrigón, Andrzej Hellmann, Bryone Kuss, David D F Ma, Fatih Demirkan, Münci Yağci, Netanel A Horowitz, Paula Marlton, Raul Cordoba, Tomasz Wrobel, Daniela Buglio, Michael Streit, Brendan P Hodkinson, Michael Schaffer, John Alvarez, Rob Ceulemans, Sriram Balasubramanian, Jan de Jong, Shean-Sheng Wang, Nele Fourneau, Wojciech Jurczak
BACKGROUND: Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. METHODS: We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma...
January 11, 2019: Lancet Haematology
https://read.qxmd.com/read/30558988/effectiveness-and-safety-of-apixaban-versus-rivaroxaban-for-prevention-of-recurrent-venous-thromboembolism-and-adverse-bleeding-events-in-patients-with-venous-thromboembolism-a-retrospective-population-based-cohort-analysis
#8
Ghadeer K Dawwas, Joshua Brown, Eric Dietrich, Haesuk Park
BACKGROUND: Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly used in routine clinical practice because of their fixed dosing and favourable pharmacological profiles. Differences in the risk of recurrent venous thromboembolism and major bleeding events between the two drugs are currently unknown. We aimed to compare the effectiveness and safety of apixaban and rivaroxaban in prevention of recurrent venous thromboembolism and major bleeding events in patients with venous thromboembolism...
December 14, 2018: Lancet Haematology
https://read.qxmd.com/read/30558987/umbralisib-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-or-mantle-cell-lymphoma-a-multicentre-phase-1-1b-study
#9
Matthew S Davids, Haesook T Kim, Alyssa Nicotra, Alexandra Savell, Karen Francoeur, Jeffrey M Hellman, Josie Bazemore, Hari P Miskin, Peter Sportelli, Laura Stampleman, Rodrigo Maegawa, Jens Rueter, Adam M Boruchov, Jon E Arnason, Caron A Jacobson, Eric D Jacobsen, David C Fisher, Jennifer R Brown
BACKGROUND: Patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do not derive durable benefit from ibrutinib monotherapy. We hypothesised that dual B-cell receptor pathway blockade would be tolerable and efficacious. We investigated a next-generation phosphoinositide-3-kinase-δ inhibitor (PI3K-δi), umbralisib, plus a Bruton tyrosine kinase inhibitor (BTKi), ibrutinib, in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma...
December 14, 2018: Lancet Haematology
https://read.qxmd.com/read/30558986/the-best-direct-acting-oral-anticoagulant-for-treatment-of-venous-thromboembolism
#10
Corinne Frere, Dominique Farge
No abstract text is available yet for this article.
December 14, 2018: Lancet Haematology
https://read.qxmd.com/read/30545577/10-day-decitabine-schedule-in-acute-myeloid-leukaemia-no-extra-bang-for-the-buck
#11
Amanda F Cashen
No abstract text is available yet for this article.
December 10, 2018: Lancet Haematology
https://read.qxmd.com/read/30545576/treatment-with-a-5-day-versus-a-10-day-schedule-of-decitabine-in-older-patients-with-newly-diagnosed-acute-myeloid-leukaemia-a-randomised-phase-2-trial
#12
Nicholas J Short, Hagop M Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M Kadia, Naval Daver, Maro Ohanian, Courtney D Dinardo, Zeev Estrov, Rashmi Kanagal-Shamanna, Abhishek Maiti, Christopher B Benton, Prithviraj Bose, Yesid Alvarado, Elias Jabbour, Steven M Kornblau, Naveen Pemmaraju, Nitin Jain, Yvonne Gasior, Mary Ann Richie, Sherry Pierce, Jorge Cortes, Marina Konopleva, Guillermo Garcia-Manero, Farhad Ravandi
BACKGROUND: Hypomethylating agents, such as decitabine, are the standard of care for older patients with newly diagnosed acute myeloid leukaemia. Single-arm studies have suggested that a 10-day schedule of decitabine cycles leads to better outcomes than the usual 5-day schedule. We compared the efficacy and safety of these two schedules. METHODS: Eligible patients were aged 60 years or older with acute myeloid leukaemia but unsuitable for intensive chemotherapy (or <60 years if unsuitable for intensive chemotherapy with an anthracycline plus cytarabine)...
December 10, 2018: Lancet Haematology
https://read.qxmd.com/read/30528137/haematological-immune-related-adverse-events-induced-by-anti-pd-1-or-anti-pd-l1-immunotherapy-a-descriptive-observational-study
#13
Nicolas Delanoy, Jean-Marie Michot, Thibault Comont, Nora Kramkimel, Julien Lazarovici, Romain Dupont, Stéphane Champiat, Claude Chahine, Caroline Robert, Charles Herbaux, Benjamin Besse, Aude Guillemin, Christine Mateus, Patricia Pautier, Philippe Saïag, Emanuela Madonna, Marie Maerevoet, Jean-Christophe Bout, Charlotte Leduc, Pascal Biscay, Gilles Quere, Charlée Nardin, Mikael Ebbo, Laurence Albigès, Grégoire Marret, Virginie Levrat, Cécile Dujon, Jacques Vargaftig, Salim Laghouati, Laure Croisille, Anne-Laure Voisin, Bertrand Godeau, Christophe Massard, Vincent Ribrag, Aurélien Marabelle, Marc Michel, Olivier Lambotte
BACKGROUND: Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related adverse events (irAEs). These adverse events can involve all organs, including the haemopoietic system. Thus far, haematological irAEs (haem-irAEs) have not been extensively characterised. This study aims to provide a comprehensive report of the haem-irAEs induced by anti-PD-1 or anti-PD-L1. METHODS: In this descriptive observational study, we included consecutive patients aged at least 18 years with grade 2 or worse haem-irAEs induced by anti-PD-1 or anti-PD-L1 immunotherapy registered in three French pharmacovigilance databases: the Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC; a prospective registry of patients treated with anti-PD-1 or anti-PD-L1 at a single centre), the ImmunoTOX committee of Gustave Roussy (a national referral database of suspected irAEs in patients treated with immunotherapy), and the registry of the Centre de Référence des Cytopénies Auto-Immunes de l'Adulte (CeReCAI; a national database of autoimmune cytopenias)...
December 4, 2018: Lancet Haematology
https://read.qxmd.com/read/30528136/characterisation-of-rare-haematological-immune-related-toxicities
#14
John B Haanen, Solange Peters
No abstract text is available yet for this article.
December 4, 2018: Lancet Haematology
https://read.qxmd.com/read/30709437/acute-gvhd-prophylaxis-plus-atlg-after-myeloablative-allogeneic-haemopoietic-peripheral-blood-stem-cell-transplantation-from-hla-identical-siblings-in-patients-with-acute-myeloid-leukaemia-in-remission-final-results-of-quality-of-life-and-long-term-outcome
#15
RANDOMIZED CONTROLLED TRIAL
Francesca Bonifazi, Carlos Solano, Christine Wolschke, Mariarosaria Sessa, Francesca Patriarca, Francesco Zallio, Arnon Nagler, Carmine Selleri, Antonio Maria Risitano, Giuseppe Messina, Wolfgang Bethge, Pilar Herrera, Anna Sureda, Angelo Michele Carella, Michele Cimminiello, Stefano Guidi, Jürgen Finke, Roberto Sorasio, Christelle Ferra, Jorge Sierra, Domenico Russo, Edoardo Benedetti, Giuseppe Milone, Fabio Benedetti, Marion Heinzelmann, Domenico Pastore, Manuel Jurado, Elisabetta Terruzzi, Franco Narni, Andreas Völp, Francis Ayuk, Tapani Ruutu, Nicolaus Kröger
BACKGROUND: We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse and infections, and improves cGVHD-free and relapse-free survival (cGRFS)...
February 2019: Lancet Haematology
https://read.qxmd.com/read/30709436/prevalence-symptom-burden-and-natural-history-of-deep-vein-thrombosis-in-people-with-advanced-cancer-in-specialist-palliative-care-units-hidden-a-prospective-longitudinal-observational-study
#16
Clare White, Simon I R Noble, Max Watson, Flavia Swan, Victoria L Allgar, Eoin Napier, Annmarie Nelson, Jayne McAuley, Jennifer Doherty, Bernadette Lee, Miriam J Johnson
BACKGROUND: The prevalence of deep venous thrombosis in patients with advanced cancer is unconfirmed and it is unknown whether current international thromboprophylaxis guidance is applicable to this population. We aimed to determine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palliative care units (SPCUs). METHODS: We did this prospective longitudinal observational study in five SPCUs in England, Wales, and Northern Ireland (four hospices and one palliative care unit)...
February 2019: Lancet Haematology
https://read.qxmd.com/read/30709435/novel-pathway-inhibitors-for-the-treatment-of-chronic-lymphocytic-leukaemia
#17
Stefano Molica, Emili Montserrat
No abstract text is available yet for this article.
February 2019: Lancet Haematology
https://read.qxmd.com/read/30709434/in-vivo-t-cell-depletion-burden-of-morbidity-versus-survival
#18
Mary Eapen
No abstract text is available yet for this article.
February 2019: Lancet Haematology
https://read.qxmd.com/read/30709433/is-venous-thromboembolism-a-problem-in-patients-with-cancer-in-palliative-care
#19
Per Morten Sandset, Anders E A Dahm
No abstract text is available yet for this article.
February 2019: Lancet Haematology
https://read.qxmd.com/read/30709432/to-treat-or-not-to-treat-the-dilemma-for-pregnant-women
#20
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
February 2019: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"